The drug mirdametinib was once shelved by Pfizer. Today, it’s Gomekli – an FDA-approved treatment and the first ever for both children and adults with NF1.
A new PharmaVoice article reveals how CTF recognized the drug’s potential when others didn’t, advocated for its continued development, and helped connect the path to its advancement by SpringWorks Therapeutics.
This breakthrough demonstrates what’s possible when science, strategy, and urgency align – and when promising treatments are given a second chance through drug repositioning.
As the drug discovery engine for NF, we’ll always work to ensure valuable treatments don’t “die in the fridge.”
